Dupilumab Improves Itch, Skin Pain, and Sleep in Adult Patients With Prurigo Nodularis (LIBERTY PN-PRIME and PRIME2)

Background: Prurigo nodularis (PN) is characterized by the presence of itchy nodules on the trunk/extremities, often accompanied by skin pain and sleep disruption. Psychometric validation and within-patient meaningful change thresholds for 3 patient-reported outcome instruments have been assessed in patients with PN: Worst Itch Numerical Rating Scale (WI-NRS), Skin Pain-NRS, and Sleep-NRS. The proportion of patients achieving clinically meaningful improvement in these scores was investigated in 2 pooled randomized, double-blind, placebo-controlled, phase 3 trials of dupilumab in adults with PN uncontrolled on topical therapies, LIBERTY-PN PRIME (NCT04183335) and PRIME2 (NCT04202679).